Moleculin Biotech
MBRX
5 hedge funds and large institutions have $254K invested in Moleculin Biotech in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
17% less funds holding
Funds holding: 6 → 5 (-1)
22% less capital invested
Capital invested by funds: $326K → $254K (-$72K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$72.1K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
+$14.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$124K |
| 2 |
Morgan Stanley
New York
|
-$14.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14.4K |
| 4 |
Barclays
London,
United Kingdom
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IG
1
ING Group
Amsterdam,
Netherlands
| $122K | – | – | – |
|
|
VKH
2
Virtu KCG Holdings
New York
| $66K | +$72.1K | +5 | New |
|
3
Citigroup
New York
| $29K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $14K | +$14.4K | +1 | New |
|
|
AIM
5
Acrospire Investment Management
Chicago,
Illinois
| $9K | +$14.4K | +1 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5K | -$14.4K | -1 | Closed |
|
|
7
Morgan Stanley
New York
| $4K | -$14.4K | -1 | Closed |
|
|
NFG
8
Next Financial Group
Houston,
Texas
| $3K | – | – | – |
|
|
WA
9
WFG Advisors
Dallas,
Texas
| $2K | – | – | – |
|
|
SIM
10
Spark Investment Management
New York
| – | -$124K | -8 | Closed |
|
|
11
Barclays
London,
United Kingdom
| – | -$9K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q3 2016 in Review
5 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2016, worth a combined $254K — down 22% from $326K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MBRX and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $72.1K. The largest seller was Spark Investment Management, exiting entirely with an estimated $124K sold.
- 5 institutional investors held Moleculin Biotech (MBRX) as of Q3 2016, down from 6 in Q2 2016.
- Funds reported $254K of Moleculin Biotech stock for Q3 2016, down 22% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q3 2016 and 4 closed out, a net change of -1 holder.
- The largest Moleculin Biotech buyer in Q3 2016 was Virtu KCG Holdings, an estimated $72.1K added.
- The largest Moleculin Biotech seller in Q3 2016 was Spark Investment Management, an estimated $124K sold.
Based on aggregated 13F filings for Q3 2016.